Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serological and biochemical studies were done at the National Taiwan University Hospital, on 243 patients with biopsy-proved anaplastic nasopharyngeal carcinoma (NPC) in various clinical conditions. The remarkable elevation of both IgG and IgA antibody titers against EB virus was specific for NPC patients. The seropositive rates ranged from 75% to 100% in various stages of NPC patients. Serum IgG and IgA levels were also increased moderately and nonspecifically in stages II-IV and recurrent patients. Peripheral white blood cell count was also slightly increased in these patients. Peripheral lymphocyte counts were slightly decreased in patients with neck recurrence or distant metastasis. Serum IgM, C3, C4 and Acid phosphatase levels were within normal range in all the patients. Serum GOT, GPT, alkaline phosphatase, and lactate dehydrogenase were elevated in some of patients with distant metastasis and in most of those with liver metastasis. Mucoprotein was elevated in about 10% of stage II-IV patients but in about 50% of patients with recurrent neck metastasis or distant metastasis. in conclusion, serological and biochemical examinations are important in the diagnosis of late stages and recurrence or metastasis of NPC.
 ...
PMID:[Serological and biochemical studies in late stage of nasopharyngeal carcinoma]. 631 98

We measured serum guanase (EC 3.5.4.3) activity in patients with various diseases and in healthy controls, and evaluated the clinical usefulness of this enzyme in liver diseases. The reference range, which showed no significant difference between sexes and ages over the range studied, was 0 to 1.8 U/L. The mean guanase activities for patients with various liver diseases, including acute hepatitis, chronic hepatitis, liver cirrhosis, hepatoma and metastatic carcinoma, were above the upper limit of the reference range. In acute hepatitis and metastatic carcinoma of the liver, the activities were especially high. Validity (sensitivity + specificity) of guanase, which in all tests was above 1.66, was compared to that of AST and ALT in liver diseases. With guanase, the highest validity (1.98) was found in acute hepatitis and metastatic carcinoma. Specificity of guanase was 0.98, whereas sensitivity of AST was 1.00 in all diseases. Sensitivity and specificity of ALT were 0.85 to 0.97 in all diseases. As guanase was specific, including this enzyme with other liver function tests, such as AST and ALT, may decrease false-positive results and may be effective for prediction of liver disease.
 ...
PMID:Clinical evaluation of serum guanase activity in liver diseases. 649 63

The bone marrow activity in the liver-spleen (RES) scintigraphy has been difficult to estimate correctly. If the activity of the bone marrow is to be decided as counts/time unit it is of importance that structures with a high activity as the liver and spleen are excluded from the registration. A dorsal registration of the pelvis during 180 s will give a rather correct information of bone marrow activity and besides an image of the pelvic bone marrow is obtained. Using 270 to 280 MBq 99Tcm-Albures all 45 normal cases had values below 150 KCNT (1 KCNT = 1 000 counts). All cases with cirrhosis (n = 15) or metastases in the liver (n = 14) had values over 150 KCNT. Values over 150 KCNT were also found in 29 of 34 patients with an increase in ASAT and ALAT (GOT, GPT) as the only pathologic finding and in 12 of 21 patients with a carcinoma but without metastases in the liver.
 ...
PMID:Recording of bone marrow activity in liver-spleen (RES) scintigraphy. 652 33

One hundred and twelve patients with evaluable genitourinary tumors were treated with cis-diamminedichloroplatinum (II) as a single agent under multi-institutional clinical trials. Most patients had extensive prior therapy. Of 30 patients with testicular tumors, 5 complete responses (16.7%) and 15 partial responses (50.0%), of 29 patients with bladder carcinoma, 2 CR (6.9%) and 7 PR (24.1%), of 34 patients with prostatic carcinoma, 6 PR (17.6%), and of 10 patients with pelvis and ureter carcinoma, 1 CR and 3 PR were obtained respectively. No responder was seen in eight patients with renal cell carcinoma and in one with urethral carcinoma. Adverse reactions were similar to those already reported including gastrointestinal reactions, nephrotoxicity and myelosuppression. Ototoxicity, peripheral neuropathies and transient elevation of GOT-GPT levels were occasionally encountered. Cis-diamminedichloroplatinum (II) appears to be highly active as a single agent in the treatment of advanced genitourinary tumors.
 ...
PMID:[Phase II study of cis-diamminedichloroplatinum (II) in genitourinary cancer]. 676 7

In response to extrahepatic neoplasms, ornithine aminotransferase, malic enzyme, alanine aminotransferase and glucokinase activity of the 'uninvolved' liver is diminished and that of hexokinase is increased. Comparison of rats at various times after the implantation of ascites tumor, mammary carcinoma, fibrosarcoma and Morris hepatomas indicate that the faster the growth rate of tumors, the earlier the onset of these hepatic changes. The results also show that, when the different tumors are the same size, the magnitude of the enzymic deviations in the liver is directly related to characteristic growth rate of the tumor lines. These and previous observations on other host tissues suggest that tumor-doubling time, which is a known factor in metastatic spread and survival, may also be a variable in the production of systemic agents through which neoplasms affect the metabolic state of the cancer host.
 ...
PMID:Effect of tumors with different growth rates on enzymes in host liver. 687 35

We determined the serum molybdenum concentration by neutron activation analysis in apparently healthy subjects and in patients with diseases of the liver and biliary system. The level was found to be markedly elevated in the initial phase of acute viral hepatitis (mean +/- S.D. 3.10 +/- 1.46 ng/ml vs. 0.55 +/- 0.21 in controls) and to return to normal during convalescence, in parallel with the liver function tests. The most significant correlations were found between the serum molybdenum concentration and the serum levels of GOT ( r = 0.710, p less than 0.001) and GPT (r = 0.683, p less than 0.001). Besides, the serum molybdenum level (mean +/- S.D.) was observed to be definitely increased in patients with HBsAg-positive chronic active hepatitis (0.97 +/- 0.49 ng/ml), HBsAg-positive liver cirrhosis (1.01 +/- 0.50), alcoholic liver disease (1.32 +/- 0.56), liver metastases (1.40 +/-0.39), gallstones (1.28 +/- 0.38), tumors of the gallbladder or extrahepatic bile ducts (1.64 +/- 0.44), and carcinoma of the head of the pancreas (1.61 +/- 0.91). Finally, the serum molybdenum level was found to be raised in two patients with primary biliary cirrhosis and in two out of four patients with drug-induced liver injury. The etiologic mechanism and the clinical importance of the observed abnormality remain to be established. Our study enlarges the existing information concerning the disorders of trace element metabolism in liver diseases.
 ...
PMID:Serum molybdenum in diseases of the liver and biliary system. 720 61

This article reports the clinical characteristics of 38 cases of patients with hepatitis B (HB) which developed into primary hepatocyte carcinoma (PHC), during a period of observation for 2-28 years (average 11.4 years). These patients were admitted repeatedly for 2 to 12 times (average 3.4 times). The clinical characteristics of the development of the symptoms in these patients were as follows: 1. Liver function fluctuated again and again. Ninety percent of these patients with HB developed liver cirrhosis (LC). Subsequently they developed into PHC. 2. HBV markers were positive over a long period of observation. During the phases of LC and PHC the rates of positive anti-HBe were 23.5% and 54.5%, respectively (P < 0.05). Comparing with anti-HBe, the rate of positive HBeAg was lower. 3. During the phase of HB, 21.0% of these patients had elevated alpha FP (mean titer 80.0 ng/ml). During the phase of PHC, 65.8% of the patients had abnormal alpha FP (mean titer 635.9 ng/ml) (P < 0.01). Sustained high level of gamma-GT and the ratio of gamma-GT/ALT higher than 1.5 were dangerous signals (P < 0.05). The level of ALP in these patients with HB was below 170 u/L. But 50% of them had high level of ALP when they developed into PHC. During the phase of LC these patients were detected regularly with ultrasonic waves.
 ...
PMID:[The study on clinical characteristics of the development of primary hepatocyte carcinoma induced by hepatitis B]. 751 49

We evaluated the best route of administration of TNP-470, an angiogenesis inhibitor, by comparing the anti-tumour effects and toxicity following injection via the hepatic artery, the portal vein, or the jugular vein in a rabbit model of liver metastases. Following the injections of 1 x 10(6) VX2 carcinoma cells into the portal vein of rabbits, 50 mg of TNP-470 was injected continuously into the hepatic artery, portal vein, or jugular vein for 7 days. The number of tumours on the surface of the liver was counted 14 days following the start of the infusion, and the serum glutamic-oxaloacetic transamine (GOT), glutamic-pyruvic transaminase (GPT) and total bilirubin concentrations were examined. In addition, a coloured silicon rubber was injected into the vessels of the liver to visualise the capillary networks around the tumours and assess the degree of suppression of angiogenesis by TNP-470. The mean number of tumours following intra-arterial injection (17.5 +/- 2.9) was significantly less than the control (237.0 +/- 34.0) (P < 0.05). The mean numbers of the tumours following intraportal (89.1 +/- 16.0) and intravenous (140.6 +/- 31.2) injection were both less than the controls (215.3 +/- 45.5, 284.8 +/- 55.4 respectively), but the differences were not significant. We conclude that intra-arterial injection of TNP-470 is the most effective method for preventing liver metastases in this model.
 ...
PMID:Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. 754 15

Two dogs with metabolic epidermal necrosis had hyperkeratosis of the footpads accompanied by erythematous, erosive and crusting lesions affecting the muzzle, external genitalia, perineum and periocular regions. Histopathological examination of skin biopsies revealed a superficial hydropic dermatitis with marked parakeratosis. Both dogs had high plasma activities of alkaline phosphatase and alanine aminotransferase and high concentrations of glucose, and also a marked hypoaminoacidaemia. Despite these similarities, the cutaneous eruptions were associated with different underlying diseases. One dog had a pancreatic carcinoma which had metastasised widely; the primary tumour and the metastases showed glucagon immunoreactivity on immunocytochemical staining, and the dog's plasma glucagon concentration was markedly greater than that of control dogs. The other dog had diffuse hepatic disease; its plasma glucagon concentration was similar to that of control samples and cirrhosis was identified post mortem. Metabolic epidermal necrosis in dogs is a distinct cutaneous reaction pattern which may be associated with different underlying systemic diseases; however, the pathogenesis of the skin lesions remains unclear.
 ...
PMID:Metabolic epidermal necrosis in two dogs with different underlying diseases. 763 36

The medical and necropsy records of 41 cats diagnosed with nonlymphomatous hepatobiliary (NLHB) masses, including neoplasia and cysts, were reviewed. Overall, benign masses (n = 27) were more common than malignant ones (n = 14). The single most common malignancy was cholangiocellular carcinoma. The median age at diagnosis was significantly lower (P < .01) for cats with malignant rather than benign disease. Clinical signs associated with hepatobiliary neoplasia were usually vague and included lethargy, vomiting, and anorexia, often present for at least 2 weeks before presentation. Benign masses were an incidental finding in significantly more (P < .01) of the cases than were malignant masses. Median values for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin were significantly higher (P < .05) in cats with malignant versus benign masses. The prognosis for malignant disease was poor, with 86% of the cats dying or being euthanatized during hospitalization. Cats with benign disease that underwent exploratory celiotomy were more likely to recover and warranted a more favorable prognosis than cats with malignant tumors. Factors associated with malignancy included age at presentation, presence of clinical signs at presentation, and specific serum chemistry changes.
 ...
PMID:Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972 to 1991). 783 94


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>